Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says

(By Ed Silverman for STAT)

The newly approved1 Sarepta Therapeutics drug for Duchenne muscular dystrophy2 will cost about $300,000 a year for the average patient in the United States, which is less than what some Wall Street analysts had expected.  Continue reading article here……


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or